Breaking News Instant updates and real-time market news.

ADAP

Adaptimmune

$6.40

-0.39 (-5.74%)

18:07
10/09/16
10/09
18:07
10/09/16
18:07

Adaptimmune reports data on NY-ESO SPEAR T-cell receptor therapy

Adaptimmune Therapeutics announced a presentation of updated data on its lead clinical program, an NY-ESO SPEAR T-cell receptor therapy, in patients with synovial sarcoma at the European Society for Medical Oncology 2016 Congress. The study included Cohort 1: Subjects with high NY-ESO-1 antigen expression and lymphodepletion with cyclophosphamide and fludarabine; Cohort 2: Subjects with low NY-ESO-1 antigen expression and lymphodepletion with cyclophosphamide and fludarabine; Cohort 3: Subjects with high NY-ESO-1 antigen expression and lymphodepletion with cyclophosphamide alone -- no fludarabine; and Cohort 4: Subjects with high NY-ESO-1 antigen expression and lymphodepletion with a modified lower dose than Cohort I of cyclophosphamide and fludarabine. In Cohort 1, the median duration of response is reported to be approximately 31 weeks as of the August 31 data cutoff. Ongoing NY-ESO SPEAR T-cell persistence has been observed for up to 36 months. In Cohort 2, four subjects of a targeted 10 are currently enrolled in the second cohort; three patients have been treated with NY-ESO SPEAR T-cells. As of August 31, best responses seen in these three patients were: one partial response, one stable disease, and one progressive disease. In Cohorts 3 and 4, five patients are currently enrolled in the third cohort; no objective responses have been observed to date. As pre-specified in the protocol, enrollment in cohort 3 has ceased, and company has initiated enrollment in Cohort 4. NY-ESO SPEAR T-cells continue to demonstrate a generally acceptable benefit:risk profile in all treated patients to date. Most common toxicities related to therapy can be monitored and managed with medical intervention and supportive care. While there are differences in the patient populations, incidence of cytokine release syndrome with NY-ESO-1c259 SPEAR T appears to be of lower frequency and severity than reported with CD19 CAR-T therapy. As previously reported at the 2016 Annual American Society of Clinical Oncology Meeting, there was one fatal SAE of bone marrow failure in Cohort 2 of the synovial sarcoma trial. Internal investigations have not identified a mechanism by which NY-ESO SPEAR T-cells may have caused bone marrow failure.

  • 09

    Oct

ADAP Adaptimmune
$6.40

-0.39 (-5.74%)

02/25/16
02/25/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Boston Scientific (BSX) initiated with a Buy at SunTrust by analyst Bruce Nudell, who expects an organic growth accelerating through 2018 driven by structural heart sales and core market stabilization. 2. Kite Pharma (KITE) initiated with a Buy, with analyst Robyn Karnauskas saying that Kite's technology could be the first to market and its data in the largest blood cancer market look similar to competition. The analyst also started Juno Therapeutics (JUNO) and Adaptimmune (ADAP) with Buy ratings. 3. Insulet (PODD) initiated with a Sell at Empire by analyst Cathy Reese, who said the company has several issues with its OmniPod System that will not be remedied with planned upgrades. 4. Biogen (BIIB) initiated with a Buy at Citi. 5. Crown Castle (CCI) initiated with a Buy at SunTrust. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/04/16
LEER
08/04/16
NO CHANGE
LEER
Outperform
Adaptimmune partial clinical hold on planned trial 'surprising,' says Leerink
Leerink analyst Michael Schmidt sees the announced partial clinical hold on Adaptimmune's liposarcoma study as "surprising" and notes that it introduces some additional risk. However, the analyst says the news does not "fundamentally" change his investment thesis on Adaptimmune as he expects a rapid resolution. Schmidt reiterates an Outperform rating on the shares.
08/26/16
SBSH
08/26/16
NO CHANGE
SBSH
Buy
Adaptimmune partial clinical hold may be lifted within weeks, says Citi
Citi analyst Robyn Karnauskas said that after traveling with several members of Adaptimmune's management team, including its CEO and CFO, she came away feeling that their TCR platform remains in the lead despite delays. The FDA's partial clinical hold in myxoid round cell liposarcoma, or MRCLS, was not related to safety or efficacy of the product and Karnauskas sees the potential for the FDA to possibly reverse the partial clinical hold within a few weeks, she tells investors. Citi keeps a Buy rating on Adaptimmune shares.
09/30/16
RAJA
09/30/16
INITIATION
Target $16
RAJA
Outperform
Adaptimmune initiated with an Outperform at Raymond James
Raymond James analyst Reni Benjamin initiated Adaptimmune with a Buy and a $16 price target saying it is a leading player in the engineered T cell receptor therapy space, with a growing product portfolio concentrating primarily in the solid tumor market.

TODAY'S FREE FLY STORIES

AOS

A.O. Smith

$54.42

1.45 (2.74%)

20:16
04/27/17
04/27
20:16
04/27/17
20:16
Downgrade
A.O. Smith rating change  »

A.O. Smith downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

FB

Facebook

$147.70

1.14 (0.78%)

20:11
04/27/17
04/27
20:11
04/27/17
20:11
Hot Stocks
Facebook improves 'Rights Manager' content protection system »

Facebook introduced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 08

    May

  • 16

    May

AAWW

Atlas Air

$59.80

0.4 (0.67%)

20:11
04/27/17
04/27
20:11
04/27/17
20:11
Downgrade
Atlas Air rating change  »

Atlas Air downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 24

    May

UTHR

United Therapeutics

$120.50

0.51 (0.43%)

20:00
04/27/17
04/27
20:00
04/27/17
20:00
Hot Stocks
United Therapeutics announces $250M repurchase program »

United Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

CLDR

Cloudera

19:57
04/27/17
04/27
19:57
04/27/17
19:57
Syndicate
Cloudera 15M share IPO priced at $15.00, above the range »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 28

    Apr

CYTR

CytRx

$0.68

-0.121 (-15.02%)

19:56
04/27/17
04/27
19:56
04/27/17
19:56
Hot Stocks
CytRx: Former 'SPA' for aldoxorubicin no longer applicable »

CytRx disclosed in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

EEX

Emerald Expositions Events

19:52
04/27/17
04/27
19:52
04/27/17
19:52
Syndicate
Emerald Expositions Events 15.5M share IPO priced at $17.00 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

GOOG

Alphabet

$874.25

2.52 (0.29%)

, GOOGL

Alphabet Class A

$891.44

2.3 (0.26%)

19:31
04/27/17
04/27
19:31
04/27/17
19:31
Hot Stocks
Google introduces development kit for Google Assistant »

Google announced in a…

GOOG

Alphabet

$874.25

2.52 (0.29%)

GOOGL

Alphabet Class A

$891.44

2.3 (0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

  • 16

    May

  • 22

    May

SRPT

Sarepta

$34.72

-0.14 (-0.40%)

19:26
04/27/17
04/27
19:26
04/27/17
19:26
Hot Stocks
Sarepta: 'Productive' payer talks, ramping of patient starts continuing in Q2 »

"The number of exon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

SRPT

Sarepta

$34.72

-0.14 (-0.40%)

19:22
04/27/17
04/27
19:22
04/27/17
19:22
Hot Stocks
Sarepta: Guidance includes only U.S. sales »

"Our guidance only…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

SRPT

Sarepta

$34.72

-0.14 (-0.40%)

19:20
04/27/17
04/27
19:20
04/27/17
19:20
Hot Stocks
Sarepta: Exondys post-market commitment data likely unavailable for couple years »

"The final protocols…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

SRPT

Sarepta

$34.72

-0.14 (-0.40%)

19:18
04/27/17
04/27
19:18
04/27/17
19:18
Hot Stocks
Sarepta confirms CEO Ed Kaye to resign from role at end of current term »

Sarepta confirmed in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

BSAC

Santander Chile

$23.59

-0.36 (-1.50%)

19:02
04/27/17
04/27
19:02
04/27/17
19:02
Earnings
Santander Chile reports Q1 EPS 46c, consensus 42c »

Reports Q1 ROAE up 140…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

BA

Boeing

$183.22

1.51 (0.83%)

, BDRBF

Bombardier

$1.63

-0.0278 (-1.67%)

19:01
04/27/17
04/27
19:01
04/27/17
19:01
Hot Stocks
Canada gov't objects to Boeing allegations over Bombardier pricing in U.S. »

The Government of Canada…

BA

Boeing

$183.22

1.51 (0.83%)

BDRBF

Bombardier

$1.63

-0.0278 (-1.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

BA

Boeing

$183.22

1.51 (0.83%)

, BDRBF

Bombardier

$1.63

-0.0278 (-1.67%)

18:56
04/27/17
04/27
18:56
04/27/17
18:56
Periodicals
Boeing requests U.S. take action on Bombardier C series prices in U.S., FT says »

Boeing (BA) is aiming to…

BA

Boeing

$183.22

1.51 (0.83%)

BDRBF

Bombardier

$1.63

-0.0278 (-1.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

SWN

Southwestern Energy

$7.67

-0.16 (-2.04%)

18:48
04/27/17
04/27
18:48
04/27/17
18:48
Earnings
Southwestern Energy reports Q1 adjusted EPS 18c, consensus 18c »

Reports Q1 revenue $846M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

CRMD

CorMedix

$1.04

-0.07 (-6.31%)

18:43
04/27/17
04/27
18:43
04/27/17
18:43
Syndicate
CorMedix files to sell common stock warrants, no amount given »

H.C. Wainwright & Co.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 28

    Apr

FET

Forum Energy

$18.10

-1.05 (-5.48%)

18:39
04/27/17
04/27
18:39
04/27/17
18:39
Earnings
Breaking Earnings news story on Forum Energy »

Forum Energy sees Q2 EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

WDC

Western Digital

$85.71

1.1 (1.30%)

18:38
04/27/17
04/27
18:38
04/27/17
18:38
Hot Stocks
Western Digital: NAND supply-demand likely favorable through 'at least' 1H18 »

"Industry-wide…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

FET

Forum Energy

$18.10

-1.05 (-5.48%)

18:38
04/27/17
04/27
18:38
04/27/17
18:38
Earnings
Forum Energy reports Q1 adjusted EPS (14c), consensus (16c) »

Reports Q1 revenue $171M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

SJR

Shaw Communications

$21.30

0.07 (0.33%)

18:36
04/27/17
04/27
18:36
04/27/17
18:36
Hot Stocks
Shaw Communications restores internet and phone services after brief outage »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTRX

Matrix Service

$16.88

-0.575 (-3.30%)

18:33
04/27/17
04/27
18:33
04/27/17
18:33
Earnings
Breaking Earnings news story on Matrix Service »

Matrix Service sees FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIMO

Gigamon

$36.00

-0.6 (-1.64%)

18:33
04/27/17
04/27
18:33
04/27/17
18:33
Earnings
Gigamon sees Q2 adjusted EPS 2c-7c, consensus 19c »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 12

    Jun

MTRX

Matrix Service

$16.88

-0.575 (-3.30%)

18:32
04/27/17
04/27
18:32
04/27/17
18:32
Earnings
Matrix Service sees Q3 EPS (56c)-(49c), consensus 13c »

Sees Q3 revenue $250M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WDC

Western Digital

$85.71

1.1 (1.30%)

, TOSBF

Toshiba, also use TOSYY

$1.97

-0.01 (-0.51%)

18:31
04/27/17
04/27
18:31
04/27/17
18:31
Hot Stocks
Western Digital on Toshiba chip sale: Evaluating 'full range' of alternatives »

Western Digital (WDC)…

WDC

Western Digital

$85.71

1.1 (1.30%)

TOSBF

Toshiba, also use TOSYY

$1.97

-0.01 (-0.51%)

TOSYY

Toshiba, also use TOSBF

$11.89

0.07 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.